DrugPatentWatch Database Preview

Canakinumab - Biologic Drug Details

Email this page to a colleague

Summary for canakinumab

Tradenames:	1
Patents:	40
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for canakinumab

Recent Clinical Trials for canakinumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Memorial Sloan Kettering Cancer Center	Phase 2
Novartis Pharmaceuticals	Phase 1/Phase 2
H. Lee Moffitt Cancer Center and Research Institute	Phase 1/Phase 2

See all canakinumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for canakinumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for canakinumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for canakinumab Derived from Patent Text Search

These patents were identified by searching patent claims

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	⤷ Try it Free	City of Hope (Duarte, CA)	2030-10-08	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	⤷ Try it Free	CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)	2039-02-26	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	⤷ Try it Free	SynChem, Inc. (Elk Grove Village, IL)	2032-05-31	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	⤷ Try it Free	kaleo, Inc. (Richmond, VA)	2031-01-26	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for canakinumab

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration
Denmark	2814963	⤷ Try it Free
China	104080811	⤷ Try it Free
European Patent Office	2624868	⤷ Try it Free
Israel	225636	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration